Upgrade to SI Premium - Free Trial

Stifel Reiterates Hold Rating on BioMarin Pharmaceutical Inc. (BMRN)

August 31, 2026 9:22 AM
Stifel analyst Paul Matteis reiterated a Hold rating and $70.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles